Viking Therapeutics Today VKTX Viking Therapeutics $69.04 +18.63 (+36.96%) 52-Week Range $8.28 ▼ $99.41 Price Target $111.56 Add to Watchlist Viking Therapeutics NASDAQ: VKTX is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics' earnings report for the second quarter of 2024 was impressive, capturing the attention of investors and the Viking Therapeutics' analyst community. Following the release of its ear ...

The clinical-stage biopharmaceutical company should soon be closer to potentially launching its first product. This weight loss was better than the amount achieved by Eli Lilly's Zepbound and Novo Nordisk's Wegovy in clinical trials. With VK2735 advancing into late-stage testing, investors know that Viking will be closer to potentially launching what could be a blockbuster drug. Risk-averse investors should probably stay on the sidelines with Viking. However, I think the biotech stock is a great pick for ag ...

Core Insights - Viking Therapeutics is advancing its experimental weight loss injection VK2735 into a phase three trial, potentially accelerating its development timeline by a year, with an expected launch in 2029 [3][4]. Company Developments - The company received positive feedback from the FDA, prompting the decision to move directly to a late-stage trial [3]. - Viking's shares surged by 16% in premarket trading following the announcement of the trial advancement [6]. - CEO Brian Lian indicated plans to meet with the FDA in Q4 to discuss the phase three trial's design and timing [9]. Product Details - VK2735 targets GLP-1 and GIP hormones, similar to Eli Lilly's Zepbound and Mounjaro, promoting weight loss [5]. - In a phase two trial, patients using the weekly injection lost up to 14.7% of their body weight compared to placebo [11]. - The company is also developing an oral version of VK2735, which showed a 3.3% weight loss compared to placebo in early trials [11]. - Future studies may test VK2735 as a monthly injection, offering a more convenient option than current weekly treatments [10]. Market Context - The GLP-1 market is projected to grow to $150 billion by the end of the decade, indicating significant competition among companies like Viking, Novo Nordisk, and Eli Lilly [1][7].

The results from the Phase 2 trial showed much promise with it meeting its primary and all secondary endpoints. That includes significant weight loss for those taking VK2735 when compared to patients taking a placebo. To go along with this, the company reported adjusted EPS of -20 cents in the second quarter of 2024. That's worth highlighting as it beats out Wall Street's estimate of -24 cents for the quarter. Viking Therapeutics says that it's ready to progress subcutaneous VK2735 into a Phase 3 clinical t ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2024 Earnings Conference Call July 24, 2024 4:30 PM ET Company Participants Stephanie Diaz - Manager, IR Brian Lian - President and CEO Greg Zante - CFO Conference Call Participants Asim Rana - Truist Securities Steve Seedhouse - Raymond James Jay Olson - Oppenheimer Annabel Samimy - Stifel Roger Song - Jefferies Andrew Hsieh - William Blair Rohit Bhasin - Morgan Stanley Justin Zelin - BTIG Thomas Smith - Leerink Partners Yale Jen - Laidlaw Company Operator Welcome ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other jurisd ...

Exhibit 99.1 Conference call scheduled for 4:30 p.m. ET today SAN DIEGO, July 24, 2024 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2024, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended June 30, 2024, and Other Rec ...

VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24 Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24 "The first half of 2024 was marked by strong momentum in the company's pipeline programs, as we reported successful outcomes from three different clinical trials, and began preparing for next steps with each program," stated Brian Lian, Ph.D., chief executive officer of Viking. "The Phase 2 VENTURE study of VK2735 in obesity demonstrated up to an ap ...

wragg For this particular article, we will be looking at Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) and sharing our findings about the stock, continuing the theme surrounding obesity therapies. VKTX For now, VK2735 has already reported excellent results from its phase 2 clinical trials, with 14.7% of weight loss from base line by Week 13 (subcutaneous injection) and 5.3% by Day 28 (oral). These numbers are very promising indeed, since it delivers excellent weight losses compared to NVO's Wegovy at -7% a ...

Viking's loss estimates have increased from $1.08 per share to $1.11 for 2024 and from $1.42 to $1.45 for 2025 in the past 60 days. Zacks Investment Research Surprise - Reported Earnings History 0 Earnings Whispers Without an approved/marketed product in its portfolio, the focus is expected to be on updates related to Viking's pipeline consisting of three candidates — VK2735 (for obesity), VK2809 (for non-alcoholic steatohepatitis [NASH]) and VK0214 (for X-linked adrenoleukodystrophy (X-ALD)]. Viking Therap ...